APPLICATION
ANDA075776
TYPE
ANDA
ORIGINAL APPROVAL
2002-07-01
LATEST ACTION
2020-08-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
LISINOPRIL AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, LISINOPRIL 20MG · TABLET · ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LISINOPRIL 20MG · TABLET · ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, LISINOPRIL 10MG · TABLET · ORAL
Approval history
2020-08-20Labeling · Supplement 44 · standardAP
2019-12-17Labeling · Supplement 42 · standardAP
2019-12-17Labeling · Supplement 40 · standardAP
2019-12-17Labeling · Supplement 43 · standardAP
2014-02-28Labeling · Supplement 18AP
2014-02-26Labeling · Supplement 39 · standardAP
2014-02-26Labeling · Supplement 38 · standardAP
2013-08-01Labeling · Supplement 36 · standardAP
2013-08-01Labeling · Supplement 34AP
2013-08-01Labeling · Supplement 32AP
2013-08-01Labeling · Supplement 37 · standardAP
2013-08-01Labeling · Supplement 35 · standardAP
2010-02-01Labeling · Supplement 28AP
2009-07-10Labeling · Supplement 22AP
2004-10-26Labeling · Supplement 8AP
2002-07-01OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.